Advertisement

Probiotics in Inflammatory Bowel Diseases

  • Paolo Gionchetti
  • Fernando Rizzello
  • Claudia Morselli
  • Rosy Tambasco
  • Massimo Campieri

Conclusions

Many clinical and experimental observations do suggest an involvement of the intestinal microflora in the pathogenesis and in the perpetuation of IBD. Probiotics may provide a simple and attractive way to prevent or treat IBD, and patients find the probiotic concept appealing because it is safe, non-toxic and natural. A highly concentrated cocktail of probiotics (VSL#3) is effective in the prevention of pouchitis onset and relapses. Results in ulcerative colitis are promising both in prevention of relapses and treatment of mild to moderate attacks. Results in Crohn’s disease are not yet clear because of conflicting data and the limited number of well-performed studies.

It is important to select a well-characterised probiotic preparation; in fact viability and survival of bacteria in many available preparations are unproven. It should be remembered that the beneficial effect of one probiotic preparation does not imply the efficacy of other preparations containing different bacterial strains, because each individual probiotic strain has unique biological properties. There is the need to improve our knowledge on the composition of enteric flora or “the neglected organ” and of the intestinal physiology and its relationship with the luminal ecosystem.

Keywords

Inflammatory Bowel Disease Ulcerative Colitis Ileostomy Closure Chronic Pouchitis Saccharomyces Boulardii 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Guarner F, Casellas F, Borruel N et al (2002) Role of microecology in chronic inflammatory bowel diseases. Eur J Clin Nutr 56(Suppl 4):S34–S38PubMedCrossRefGoogle Scholar
  2. 2.
    Duchmann R, Kaiser I, Hermann E et al (1995) Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 102:104–108Google Scholar
  3. 3.
    MacPherson A, Khoo UY, Forgacs I et al (1996) Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut 38:365–375PubMedGoogle Scholar
  4. 4.
    Janowitz HD, Croen EC, Sachar DB (1998) The role of the faecal stream in Crohn’s disease: an historical and analytic perspective. Inflamm Bowel Dis 4:29–39PubMedCrossRefGoogle Scholar
  5. 5.
    D’Haens GR, Geboes K, Peeters M et al (1998) Early lesions of recurrent Crohn’s disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 114:771–774Google Scholar
  6. 6.
    Neut C, Bulois P, Desreumaux P et al (2002) Changes in the bacterial flora of the neoterminal ileum after ileocolonic resection for Crohn’s disease. Am J Gastroenterol 97:939–946PubMedCrossRefGoogle Scholar
  7. 7.
    Sartor RB (1995) Insights into the pathogenesis of inflammatory bowel disease provided by new rodent models of spontaneous colitis. Inflam Bowel Dis 1:64–75CrossRefGoogle Scholar
  8. 8.
    Campieri M, Gionchetti P (1999) Probiotics in inflammatory bowel disease: new insight to pathogenesis or a possible therapeutic alternative? Gastroenterology 116:1246–1249PubMedCrossRefGoogle Scholar
  9. 9.
    Metchnikoff E (1907) The prolongation of life: optimistic studies. Heinemann, London, pp 161–183Google Scholar
  10. 10.
    Schaafsma G (1996) State of the art concerning probiotic strains in milk products. IDF Nutr News 15:23–42Google Scholar
  11. 11.
    Lee YK, Salminen S (1995) The coming age of probiotics. Trends Food Sci Technol 6:241–245CrossRefGoogle Scholar
  12. 12.
    Fabia R, Ar’rajab A, Johansson M-L et al (1993) The effect of exogenous administration of Lactobacillus reuterii R2LC and oat fiber on acetic acid-induced colitis in the rat. Scand J Gastroenterol 28:155–162PubMedGoogle Scholar
  13. 13.
    Mao Y, Nobaek S, Kasravi B et al (1996) The effects of Lactobacillus strains and oat fibre on methotrexateinduced enterocolitis in rats. Gastroenterology 111:334–344PubMedCrossRefGoogle Scholar
  14. 14.
    Madsen KL, Tavernini MM, Doyle JSG, Fedorak RN (1999) Lactobacillus sp prevents development of enterocolitis in interleukin-10 gene-deficient mice. Gastroenterology 116:1107–1114PubMedCrossRefGoogle Scholar
  15. 15.
    Schultz M, Veltkamp C, Dieleman LA et al (2002) Lactobacillus plantarum 299V in the treatment and prevention of spontaneous colitis in interleukin-10 deficient mice. Inflamm Bowel Dis 8:71–80PubMedCrossRefGoogle Scholar
  16. 16.
    O’Mahony L, Feenex M, O’Halloran S et al (2001) Probiotic impact on microbial flora, inflammation and tumour development in IL-10 knockout mice. Aliment Pharmacol Ther 15:1219–1225PubMedCrossRefGoogle Scholar
  17. 17.
    McCarthy J, O’Mahony L, O’Callaghan L et al (2003) Double-blind, placebo-controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut 52:975–980PubMedCrossRefGoogle Scholar
  18. 18.
    Shibolet O, Karmeli F, Eliakim R et al (2002) Variable response to probiotics in two models of experimental colitis in rats. Inflamm Bowel Dis 8:399–408PubMedCrossRefGoogle Scholar
  19. 19.
    Madsen K, Cornish A, Soper P et al (2001) Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 121:580–591PubMedCrossRefGoogle Scholar
  20. 20.
    Kruis W, Schuts E, Fric P (1997) Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 11:853–858PubMedCrossRefGoogle Scholar
  21. 21.
    Rembacken BJ, Snelling AM, Hawkey P (1999) Non pathogenic Escherichia coli vs mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 354:635–639PubMedCrossRefGoogle Scholar
  22. 22.
    Kruis W, Fric P, Potrotnieks J et al (2004) Maintaining remission of ulcerative colitis with Escherichia Coli Nissle 1917 is as effective as with standard mesalazine. Gut 53:1673–1623CrossRefGoogle Scholar
  23. 23.
    Venturi A, Gionchetti P, Rizzello F et al (1999) Impact on the faecal flora composition of a new probiotic preparation. Preliminary data on maintenance treatment of patients with ulcerative colitis (UC) intolerant or allergic to 5-aminosalicylic acid (5 ASA). Aliment Pharmacol Ther 13:1103–1108PubMedCrossRefGoogle Scholar
  24. 24.
    Bibiloni R, Federak RN, Tannock GW et al (2005) VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. AM J Gastroenterol 100(7):1539–1546PubMedCrossRefGoogle Scholar
  25. 25.
    Guslandi M, Giollo P, Testoni PA (2003) A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 15:697–698PubMedCrossRefGoogle Scholar
  26. 26.
    Gionchetti P, Rizzello F, Venturi A et al (2000) Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 119:305–309PubMedCrossRefGoogle Scholar
  27. 27.
    Mimura t, Rizzello F, Helwig U et al (2004) Once daily high dose probiotic therapy for maintaining remission in recurrent or refractory pouchitis. Gut 53:108–114PubMedCrossRefGoogle Scholar
  28. 28.
    Ulisse S, Gionchetti P, D’Alò S et al (2001) Increased expression of cytokines, inducible nitric oxide synthase and matrix metalloproteinases in pouchitis: effects of probiotic treatment (VSL#3). Gastroenterology 120(Suppl):A281CrossRefGoogle Scholar
  29. 29.
    Kuisma J, Mentula S, Kahri A et al (2003) Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Aliment Pharmacol Ther 17:509–515PubMedCrossRefGoogle Scholar
  30. 30.
    Gionchetti P, Rizzello F, Venturi A et al (2000) Prophylaxis of pouchitis onset with probiotic therapy: a double blind, placebo controlled trial. Gastroenterology 118:A190Google Scholar
  31. 31.
    Malchow HA (1997) Crohn’s disease and Escherichia coli. a new approach in therapy to maintain remission of colonic Crohn’s disease? J Clin Gastroenterol 25:653–658PubMedCrossRefGoogle Scholar
  32. 32.
    Guslandi M, Mezzi G, Sorghi M et al (2000) Saccharomyces boulardii in maintenance treatment of Crohn’s disease. Dig Dis Sci 45:1462–1464PubMedCrossRefGoogle Scholar
  33. 33.
    Prantera C, Scribano ML, Falasco G et al (2002) Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn’s disease: a randomised controlled trial with Lactobacillus GG. Gut 51:405–409PubMedCrossRefGoogle Scholar
  34. 34.
    Bousvaros A, Guandalini S, Baldassano RN et al (2005) A randomised, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn’s disease. Inflamm Bowel Dis 11:833–839PubMedCrossRefGoogle Scholar
  35. 35.
    Campieri M, Rizzello F, Venturi A et al (2000) Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence of Crohn’s disease: a randomised controlled study vs. mesalazine. Gastroenterology 118:A781CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2006

Authors and Affiliations

  • Paolo Gionchetti
    • 1
  • Fernando Rizzello
    • 1
  • Claudia Morselli
    • 1
  • Rosy Tambasco
    • 1
  • Massimo Campieri
    • 1
  1. 1.Department of Internal Medicine and GastroenterologyUniversity of BolognaBolognaItaly

Personalised recommendations